Palivizumab Prophylaxis: Does It Have Any Influence on the Growth and Development of the Infants?
| Autor: | Tugba Gursoy, Ismail Tavsu, Sukriye Dirman, Nazan Erbil, Fahri Ovali |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Palivizumab Pediatrics medicine.medical_specialty Cephalometry Gestational Age Respiratory Syncytial Virus Infections Antibodies Monoclonal Humanized Antiviral Agents Chemoprevention Patient Readmission law.invention Child Development Randomized controlled trial law medicine Humans Infant Very Low Birth Weight Respiratory tract infections business.industry Incidence (epidemiology) Body Weight Infant Newborn Infant Obstetrics and Gynecology Gestational age Organ Size Odds ratio Infant Low Birth Weight Anthropometry Body Height Low birth weight Treatment Outcome Infant Extremely Premature Pediatrics Perinatology and Child Health Female medicine.symptom business Head Infant Premature medicine.drug |
| Zdroj: | American Journal of Perinatology. 31:667-672 |
| ISSN: | 1098-8785 0735-1631 |
| DOI: | 10.1055/s-0033-1356485 |
| Popis: | Aim To evaluate the rehospitalization rates of premature infants who received palivizumab prophylaxis and its influence on the growth and development of these infants. Methods Infants with a gestational age of less than 32 weeks were randomized to receive prophylaxis with palivizumab (study group) or nothing (control group). Nasal swab samples were obtained monthly in all cases and also in case of infection and hospitalization. At the corrected age of 18 months Guide for Monitoring Child Development (GMCD) was administered to all patients and anthropometric indices were evaluated. Results The study was completed with 39 infants in the study group and 40 infants in the control group. Incidence of hospitalization due to respiratory syncitial virus (RSV) was found to be significantly lower in the study group both at the year of prophylaxis and in the following year (p = 0.001, odds ratio 1.32 [1.11–1.57]). There were no significant differences in terms of anthropometric indices or GMCD tests between the groups at the corrected age of 18 months. Conclusion Palivizumab reduced the incidence of lower respiratory tract infections and hospitalizations due to RSV both in the year of prophylaxis and in the following year. However, this decrease did not have any impact on the development of infants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|